NASDAQ:RVNC Revance Therapeutics (RVNC) Stock Forecast, Price & News $12.15 -0.27 (-2.17%) (As of 02:57 PM ET) Add Compare Share Share Today's Range$12.07▼$12.5950-Day Range$12.42▼$23.6352-Week Range$11.10▼$37.98Volume855,298 shsAverage Volume1.57 million shsMarket Capitalization$1.07 billionP/E RatioN/ADividend YieldN/APrice Target$33.90 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Revance Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside179.0% Upside$33.90 Price TargetShort InterestBearish16.14% of Shares Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews Sentiment-0.12Based on 14 Articles This WeekInsider TradingSelling Shares$1.72 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.26) to ($1.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.57 out of 5 starsMedical Sector237th out of 963 stocksPharmaceutical Preparations Industry96th out of 451 stocks 4.4 Analyst's Opinion Consensus RatingRevance Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $33.90, Revance Therapeutics has a forecasted upside of 179.0% from its current price of $12.15.Amount of Analyst CoverageRevance Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted16.14% of the outstanding shares of Revance Therapeutics have been sold short.Short Interest Ratio / Days to CoverRevance Therapeutics has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Revance Therapeutics has recently decreased by 0.77%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRevance Therapeutics does not currently pay a dividend.Dividend GrowthRevance Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRevance Therapeutics has received a 74.80% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Revance Therapeutics is -0.88. Previous Next 2.2 News and Social Media Coverage News SentimentRevance Therapeutics has a news sentiment score of -0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Revance Therapeutics this week, compared to 3 articles on an average week.Search Interest13 people have searched for RVNC on MarketBeat in the last 30 days. This is an increase of 8% compared to the previous 30 days.MarketBeat Follows5 people have added Revance Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Revance Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,715,930.00 in company stock.Percentage Held by InsidersOnly 3.60% of the stock of Revance Therapeutics is held by insiders.Percentage Held by Institutions93.28% of the stock of Revance Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Revance Therapeutics are expected to grow in the coming year, from ($3.26) to ($1.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Revance Therapeutics is -2.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Revance Therapeutics is -2.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRevance Therapeutics has a P/B Ratio of 81.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Revance Therapeutics (NASDAQ:RVNC) StockRevance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids; and OPUL Relational Commerce Platform, a financial technology platform. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.Read More RVNC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVNC Stock News HeadlinesSeptember 24, 2023 | americanbankingnews.comRevance Therapeutics (NASDAQ:RVNC) Trading Up 4.7%September 23, 2023 | americanbankingnews.comRevance Therapeutics, Inc. Expected to Post Q3 2023 Earnings of ($1.43) Per Share (NASDAQ:RVNC)September 27, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. September 22, 2023 | 247wallst.comGoldman Sachs Maintains Revance Therapeutics Buy RecommendationSeptember 22, 2023 | americanbankingnews.comPiper Sandler Lowers Revance Therapeutics (NASDAQ:RVNC) Price Target to $44.00September 22, 2023 | americanbankingnews.comRevance Therapeutics (NASDAQ:RVNC) Rating Reiterated by HC WainwrightSeptember 22, 2023 | americanbankingnews.comRevance Therapeutics (NASDAQ:RVNC) PT Lowered to $35.00September 22, 2023 | americanbankingnews.comRevance Therapeutics (NASDAQ:RVNC) Price Target Cut to $33.00September 27, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. September 21, 2023 | americanbankingnews.comRevance Therapeutics (NASDAQ:RVNC) Sets New 52-Week Low at $11.10September 20, 2023 | benzinga.comDiscontinuation Of Opul Business Weighs On Botox Rival Revance Therapeutics: Analyst Sees Non-Cash Impairment Charge In MillionsSeptember 19, 2023 | seekingalpha.comRevance down 16% as investor day update fails to impressSeptember 19, 2023 | markets.businessinsider.comWhat's Going On With Botox Rival Revance Therapeutics' Stock Today?September 19, 2023 | finance.yahoo.comRevance Provides Corporate Update at Investor DaySeptember 18, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Revance Therapeutics (RVNC) and PTC Therapeutics (PTCT)September 15, 2023 | msn.comRevance Therapeutics: Impressive Sales Growth/Concerning Cash BurnSeptember 15, 2023 | seekingalpha.comRevance's FDA Nod: Beauty, Brains, And Balance SheetsSeptember 6, 2023 | finance.yahoo.comRevance Therapeutics (RVNC): A Smart Investment or a Value Trap? An In-Depth ExplorationAugust 22, 2023 | finance.yahoo.comRevance to Host Investor Day on September 19, 2023August 22, 2023 | finance.yahoo.com‘Load Up,’ Says Goldman Sachs About These 2 ‘Strong Buy’ StocksAugust 21, 2023 | finance.yahoo.comRevance Therapeutics (RVNC) Shares Declined on Profit-TakingAugust 16, 2023 | msn.comExane BNP Paribas Upgrades Revance Therapeutics (RVNC)August 14, 2023 | markets.businessinsider.comGoldman Sachs Sticks to Its Buy Rating for Revance Therapeutics (RVNC)August 10, 2023 | msn.comMorgan Stanley Maintains Revance Therapeutics (RVNC) Equal-Weight RecommendationAugust 9, 2023 | benzinga.comLooking At Revance Therapeutics's Recent Unusual Options ActivityAugust 9, 2023 | benzinga.comWhere Revance Therapeutics Stands With AnalystsAugust 9, 2023 | markets.businessinsider.comMizuho Securities Remains a Buy on Revance Therapeutics (RVNC)See More Headlines Receive RVNC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RVNC Company Calendar Last Earnings8/08/2023Today9/27/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RVNC CUSIPN/A CIK1479290 Webwww.revance.com Phone(615) 724-7755Fax510-742-3401Employees534Year FoundedN/APrice Target and Rating Average Stock Price Forecast$33.90 High Stock Price Forecast$44.00 Low Stock Price Forecast$20.00 Forecasted Upside/Downside+179.0%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($4.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-356,420,000.00 Net Margins-191.93% Pretax Margin-191.55% Return on Equity-903.28% Return on Assets-58.68% Debt Debt-to-Equity Ratio14.20 Current Ratio5.12 Quick Ratio4.65 Sales & Book Value Annual Sales$132.57 million Price / Sales8.06 Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book81.00Miscellaneous Outstanding Shares87,960,000Free Float84,789,000Market Cap$1.07 billion OptionableOptionable Beta0.80 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Mark J. Foley (Age 58)CEO & Director Comp: $1.33MMr. Dustin S. Sjuts (Age 43)Pres Comp: $911.67kMr. Tobin C. Schilke (Age 48)CFO & Principal Accounting Officer Comp: $753.68kMr. Dwight Moxie (Age 47)Sr. VP, Gen. Counsel & Corp. Sec. Comp: $743.77kJessica SerraHead of Investor Relations & ESGMs. Jeanie D. HerbertSr. Director of Investor Relations & Corp. CommunicationsMs. Taryn ConwayVP of MarketingMs. Amie KrauseChief People OfficerDr. Conor GallagherHead of Medical Affairs & AestheticsDr. David A. Hollander M.B.A. (Age 49)M.D., Chief Medical Officer More ExecutivesKey CompetitorsSyndax PharmaceuticalsNASDAQ:SNDXDay One BiopharmaceuticalsNASDAQ:DAWNMannKindNASDAQ:MNKDEQRxNASDAQ:EQRXDisc MedicineNASDAQ:IRONView All CompetitorsInsiders & InstitutionsBarclays PLCBought 2,823 shares on 9/21/2023Ownership: 0.319%Dwight MoxieSold 23,853 sharesTotal: $424,821.93 ($17.81/share)Wolverine Trading LLCSold 400 shares on 8/23/2023Ownership: 0.000%Virginia Retirement Systems ET ALBought 13,700 shares on 8/22/2023Ownership: 0.016%California State Teachers Retirement SystemSold 782 shares on 8/21/2023Ownership: 0.115%View All Insider TransactionsView All Institutional Transactions RVNC Stock - Frequently Asked Questions Should I buy or sell Revance Therapeutics stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RVNC shares. View RVNC analyst ratings or view top-rated stocks. What is Revance Therapeutics' stock price forecast for 2023? 7 analysts have issued 1 year target prices for Revance Therapeutics' stock. Their RVNC share price forecasts range from $20.00 to $44.00. On average, they expect the company's stock price to reach $33.90 in the next twelve months. This suggests a possible upside of 179.0% from the stock's current price. View analysts price targets for RVNC or view top-rated stocks among Wall Street analysts. How have RVNC shares performed in 2023? Revance Therapeutics' stock was trading at $18.46 at the beginning of 2023. Since then, RVNC shares have decreased by 34.2% and is now trading at $12.15. View the best growth stocks for 2023 here. When is Revance Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our RVNC earnings forecast. How were Revance Therapeutics' earnings last quarter? Revance Therapeutics, Inc. (NASDAQ:RVNC) issued its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.72) by $0.08. The biopharmaceutical company earned $58.13 million during the quarter, compared to analyst estimates of $58.71 million. Revance Therapeutics had a negative trailing twelve-month return on equity of 903.28% and a negative net margin of 191.93%. Revance Therapeutics's revenue was up 104.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.88) EPS. What ETFs hold Revance Therapeutics' stock? ETFs with the largest weight of Revance Therapeutics (NASDAQ:RVNC) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE). What is Mark Foley's approval rating as Revance Therapeutics' CEO? 7 employees have rated Revance Therapeutics Chief Executive Officer Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among the company's employees. What other stocks do shareholders of Revance Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO). What is Revance Therapeutics' stock symbol? Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC." Who are Revance Therapeutics' major shareholders? Revance Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Capital World Investors (10.89%), JPMorgan Chase & Co. (5.34%), Thrivent Financial for Lutherans (3.69%), Alliancebernstein L.P. (2.95%), State Street Corp (2.33%) and Jennison Associates LLC (2.19%). Insiders that own company stock include Angus C Russell, Aubrey Rankin, Carey Oconnor Kolaja, Dustin S Sjuts, Dwight Moxie, Mark J Foley and Tobin Schilke. View institutional ownership trends. How do I buy shares of Revance Therapeutics? Shares of RVNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Revance Therapeutics' stock price today? One share of RVNC stock can currently be purchased for approximately $12.15. How much money does Revance Therapeutics make? Revance Therapeutics (NASDAQ:RVNC) has a market capitalization of $1.07 billion and generates $132.57 million in revenue each year. The biopharmaceutical company earns $-356,420,000.00 in net income (profit) each year or ($4.53) on an earnings per share basis. How many employees does Revance Therapeutics have? The company employs 534 workers across the globe. How can I contact Revance Therapeutics? Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The official website for the company is www.revance.com. The biopharmaceutical company can be reached via phone at (615) 724-7755, via email at jherbert@revance.com, or via fax at 510-742-3401. This page (NASDAQ:RVNC) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revance Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.